ATC
NTLA icon

Adirondack Trust Company’s Intellia Therapeutics NTLA Stock Holding History

Adirondack Trust Company’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24
Closed -$215 – 558
2025
Q4 		$215 Buy
+24
New +$330 ﹤0.01% 531

Other funds holding NTLA

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Adirondack Trust Company's NTLA Position: Q1 2026 in Review

Adirondack Trust Company sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 24 shares — an estimated $215 sold.

Adirondack Trust Company first reported a position in NTLA in Q4 2025 and held it in 1 quarter. The position peaked at $215 in Q4 2025. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Adirondack Trust Company reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Adirondack Trust Company sold 24 Intellia Therapeutics shares in Q1 2026, an estimated $215.
  • Adirondack Trust Company first reported a position in Intellia Therapeutics in Q4 2025 and held it in 1 quarter.
  • Adirondack Trust Company's Intellia Therapeutics position peaked at $215 in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Adirondack Trust Company's 13F filing for Q1 2026, filed 3 Apr 2026.